Impact of polymorphisms in the renin-angiotensin-aldosterone system on hypertrophic cardiomyopathy

JRAAS - Journal of the Renin-Angiotensin-Aldosterone System

Volumn 12, Issue 4, 2011, Pages 521-530

  Orenes Piñero, Esteban ^a   Hernández Romero, Diana ^a   Jover, Eva ^a   Valdés, Mariano ^a   Lip, Gregory Yh ^b   Marín, Francisco ^a  

^a HOSPITAL UNIVERSITARIO VIRGEN DE LA ARRIXACA   (Spain)

^b UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

Fibrosis; hypertrophic cardiomyopathy; left ventricular hypertrophy; polymorphism; renin angiotensin aldosterone system

Indexed keywords

ALDOSTERONE SYNTHASE; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN 2 RECEPTOR; ANGIOTENSINOGEN; CHYMASE; DIPEPTIDYL CARBOXYPEPTIDASE;

AMINO ACID SUBSTITUTION; ARTICLE; CONGESTIVE CARDIOMYOPATHY; DIASTOLIC DYSFUNCTION; DNA POLYMORPHISM; ENZYME ACTIVITY; EXON; GENE DELETION; GENE EXPRESSION; GENE FREQUENCY; GENE INSERTION; GENE LOCATION; GENE MUTATION; GENETIC HETEROGENEITY; GENETIC VARIABILITY; HEART ATRIUM FIBRILLATION; HEART FAILURE; HEART LEFT VENTRICLE ENDDIASTOLIC PRESSURE; HEART LEFT VENTRICLE HYPERTROPHY; HEART LEFT VENTRICLE MASS; HEART MUSCLE FIBROSIS; HEART VENTRICLE ARRHYTHMIA; HUMAN; HYPERTROPHIC CARDIOMYOPATHY; NONHUMAN; PHENOTYPE; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SARCOMERE; SUDDEN DEATH; TRANSCRIPTION INITIATION SITE;

CARDIOMYOPATHY, HYPERTROPHIC; GENETIC PREDISPOSITION TO DISEASE; HUMANS; HYPERTROPHY, LEFT VENTRICULAR; POLYMORPHISM, GENETIC; RENIN-ANGIOTENSIN SYSTEM;

EID: 83455201644     PISSN: 14703203     EISSN: 17528976     Source Type: Journal    
DOI: 10.1177/1470320311405247     Document Type: Article

References (101)

1. Ommen SR, Nishimura RA. Hypertrophic cardiomyopathy. Curr Probl Cardiol. 2004 ; 29: 239-291 (Pubitemid 38569665)
2. Elliott P, McKenna WJ. Hypertrophic cardiomyopathy. Lancet. 2004 ; 363: 1881-1891 (Pubitemid 38748646)
3. Maron BJ, Gardin JM, Flack JM, Gidding SS, Kurosaki TT, Bild DE. Prevalence of hypertrophic cardiomyopathy in a general population of young adults. Echocardiographic analysis of 4111 subjects in the CARDIA Study. Coronary Artery Risk Development in (Young) Adults. Circulation. 1995 ; 92: 785-789
4. Maron BJ, Niimura H, Casey SA, Soper MK, Wright GB, Seidman JG, et al. Development of left ventricular hypertrophy in adults in hypertrophic cardiomyopathy caused by cardiac myosin-binding protein C gene mutations. J Am Coll Cardiol. 2001 ; 38: 315-321 (Pubitemid 32721755)
5. Kaufman BD, Auerbach S, Reddy S, Manlhiot C, Deng L, Prakash A, et al. RAAS gene polymorphisms influence progression of pediatric hypertrophic cardiomyopathy. Hum Genet. 2007 ; 122: 515-23 (Pubitemid 350148963)
6. Ho CY, Seidman CE. A contemporary approach to hypertrophic cardiomyopathy. Circulation. 2006 ; 113: 858-862
7. Brito D, Richard P, Isnard R, Pipa J, Komajda M, Madeira H. Familial hypertrophic cardiomyopathy: the same mutation, different prognosis. Comparison of two families with a long follow-up. Rev Port Cardiol. 2003 ; 22: 1445-1461 (Pubitemid 38168293)
8. Marian AJ. Hypertrophic cardiomyopathy: from genetics to treatment. Eur J Clin Invest. 2010 ; 40: 360-369
9. Watkins H, Thierfelder L, Anan R, Jarcho J, Matsumori A, McKenna W, et al. Independent origin of identical beta cardiac myosin heavy-chain mutations in hypertrophic cardiomyopathy. Am J Hum Genet. 1993 ; 53: 1180-1185 (Pubitemid 23346216)
10. Marian AJ. Modifier genes for hypertrophic cardiomyopathy. Curr Opin Cardiol. 2002 ; 17: 242-252 (Pubitemid 34553628)
11. Malik FS, Lavie CJ, Mehra MR, Milani RV, Re RN. Renin-angiotensin system: genes to bedside. Am Heart J. 1997 ; 134: 514-526 (Pubitemid 27431258)
12. Day SM. Exercise in hypertrophic cardiomyopathy. J Cardiovasc Transl Res. 2009 ; 2: 407-414
13. Matsumori A, Furukawa Y, Hasegawa K, Sato Y, Nakagawa H, Morikawa Y, et al. Epidemiologic and clinical characteristics of cardiomyopathies in Japan: results from nationwide surveys. Circ J. 2002 ; 66: 323-336
14. Girolami F, Olivotto I, Passerini I, Zachara E, Nistri S, Re F, et al. A molecular screening strategy based on beta-myosin heavy chain, cardiac myosin binding protein C and troponin T genes in Italian patients with hypertrophic cardiomyopathy. J Cardiovasc Med. 2006 ; 7: 601-607 (Pubitemid 44350495)
15. Ashizawa T, Subramony SH. What is Kearns-Sayre syndrome after all?. Arch Neurol. 2001 ; 58: 1053-1054 (Pubitemid 32660766)
16. Korade-Mirnics Z, Babitzke P, Hoffman E. Myotonic dystrophy: molecular windows on a complex etiology. Nucleic Acids Res. 1998 ; 26: 1363-1368 (Pubitemid 28291607)
17. Ortlepp JR, Vosberg HP, Reith S, Ohme F, Mahon NG, Schröder D, et al. Genetic polymorphisms in the renin-angiotensin-aldosterone system associated with expression of left ventricular hypertrophy in hypertrophic cardiomyopathy: a study of five polymorphic genes in a family with a disease causing mutation in the myosin binding protein C gene. Heart. 2002 ; 87: 270-275 (Pubitemid 34177686)
18. Perkins MJ, Van Driest SL, Ellsworth EG, Will ML, Gersh BJ, Ommen SR, et al. Gene-specific modifying effects of pro-LVH polymorphisms involving the renin-angiotensin-aldosterone system among 389 unrelated patients with hypertrophic cardiomyopathy. Eur Heart J. 2005 ; 26: 2457-2462 (Pubitemid 41552976)
19. Kim S, Iwao H. Molecular and cellular mechanisms of angiotensin II-mediated cardiovascular and renal diseases. Pharmacol Rev. 2000 ; 52: 11-34 (Pubitemid 30127593)
20. Deinum J, van Gool JM, Kofflard MJ, ten Cate FJ, Danser AH. Angiotensin II type 2 receptors and cardiac hypertrophy in women with hypertrophic cardiomyopathy. Hypertension. 2001 ; 38: 1278-1281 (Pubitemid 34033402)
21. van Kesteren CA, Danser AH, Derkx FH, Dekkers DH, Lamers JM, Saxena PR, et al. Mannose 6-phosphate receptor-mediated internalization and activation of prorenin by cardiac cells. Hypertension. 1997 ; 30: 1389-1396 (Pubitemid 27528080)
22. Pagliaro P, Penna C. Rethinking the renin-angiotensin system and its role in cardiovascular regulation. Cardiovasc Drugs Ther. 2005 ; 19: 77-87 (Pubitemid 40767775)
23. Cambronero F, Marín F, Roldán V, Hernández-Romero D, Valdés M, Lip GY. Biomarkers of pathophysiology in hypertrophic cardiomyopathy: implications for clinical management and prognosis. Eur Heart J. 2009 ; 30: 139-151
24. Bonne G, Carrier L, Richard P, Hainque B, Schwartz K. Familial hypertrophic cardiomyopathy: from mutations to functional defects. Circ Res. 1998 ; 83: 580-593 (Pubitemid 28427741)
25. Elliott K, Watkins H, Redwood CS. Altered regulatory properties of human cardiac troponin I mutants that cause hypertrophic cardiomyopathy. J Biol Chem. 2000 ; 275: 22069-22074 (Pubitemid 30621785)
26. Ashrafian H, Redwood C, Blair E, Watkins H. Hypertrophic cardiomyopathy: a paradigm for myocardial energy depletion. Trends Genet. 2003 ; 19: 263-268 (Pubitemid 36507008)
27. Merante F, Tein I, Benson L, Robinson BH. Maternally inherited hypertrophic cardiomyopathy due to a novel T-to-C transition at nucleotide 9997 in the mitochondrial tRNA(glycine) gene. Am J Hum Genet. 1994 ; 55: 437-446
28. Lodi R, Cooper JM, Bradley JL, Manners D, Styles P, Taylor DJ, et al. Deficit of in vivo mitochondrial ATP production in patients with Friedreich ataxia. Proc Natl Acad Sci U S A. 1999 ; 96: 11492-11495 (Pubitemid 29487408)
29. Lele SS, Thomson HL, Seo H, Belenkie I, McKenna WJ, Frenneaux MP. Exercise capacity in hypertrophic cardiomyopathy. Role of stroke volume limitation, heart rate, and diastolic filling characteristics. Circulation. 1995 ; 92: 2886-2894
30. Shigematsu Y, Hamada M, Mukai M, Matsuoka H, Sumimoto T, Hiwada K. Mechanism of atrial fibrillation and increased incidence of thromboembolism in patients with hypertrophic cardiomyopathy. Jpn Circ J. 1995 ; 59: 329-336
31. Ogimoto A, Hamada M, Nakura J, Miki T, Hiwada K. Relation between angiotensin-converting enzyme II genotype and atrial fibrillation in Japanese patients with hypertrophic cardiomyopathy. J Hum Genet. 2002 ; 47: 184-189 (Pubitemid 34496178)
32. Maron BJ, Olivotto I, Spirito P, Casey SA, Bellone P, Gohman TE, et al. Epidemiology of hypertrophic cardiomyopathy-related death. Revisited in a large nonreferral- based patient population. Circulation. 2000 ; 102: 858-864
33. Maron BJ, Anan TJ, Roberts WC. Quantitative analysis of the distribution of cardiac muscle cell disorganization in the left ventricular wall of patients with hypertrophic cardiomyopathy. Circulation. 1981 ; 63: 882-894 (Pubitemid 11146904)
34. Varnava AM, Elliott PM, Mahon N, Davies MJ, McKenna WJ. Relation between myocyte disarray and outcome in hypertrophic cardiomyopathy. Am J Cardiol. 2001 ; 88: 275-279 (Pubitemid 32721955)
35. Furlan AJ, Craciun AR, Raju NR, Hart N. Cerebrovascular complications associated with idiopathic hypertrophic subaortic stenosis. Stroke. 1984 ; 15: 282-284 (Pubitemid 14171262)
36. Maron BJ. Hypertrophic cardiomyopathy: a systematic review. JAMA. 2002 ; 287: 1308-1320 (Pubitemid 34250486)
37. Solomon SD, Wolff S, Watkins H, Ridker PM, Come P, McKenna WJ, et al. Left ventricular hypertrophy and morphology in familial hypertrophic cardiomyopathy associated with mutations of the beta-myosin heavy chain gene. J Am Coll Cardiol. 1993 ; 22: 498-505 (Pubitemid 23214563)
38. Pfeufer A, Osterziel KJ, Urata H, Borck G, Schuster H, Wienker T, et al. Angiotensin-converting enzyme and heart chymase gene polymorphisms in hypertrophic cardiomyopathy. Am J Cardiol. 1996 ; 78: 362-364 (Pubitemid 26265286)
39. Ishanov A, Okamoto H, Yoneya K, Watanabe M, Nakagawa I, Machida M, et al. Angiotensinogen gene polymorphism in Japanese patients with hypertrophic cardiomyopathy. Am Heart J. 1997 ; 133: 184-189
40. Brugada R, Kelsey W, Lechin M, Zhao G, Yu QT, Zoghbi W, et al. Role of candidate modifier genes on the phenotypic expression of hypertrophy in patients with hypertrophic cardiomyopathy. J Investig Med. 1997 ; 45: 542-551 (Pubitemid 127806488)
41. Osterop AP, Kofflard MJ, Sandkuijl LA, ten Cate FJ, Krams R, Schalekamp MA, et al. AT1 receptor A/C1166 polymorphism contributes to cardiac hypertrophy in subjects with hypertrophic cardiomyopathy. Hypertension. 1998 ; 32: 825-830 (Pubitemid 28530214)
42. Kupari M, Hautanen A, Lankinen L, Koskinen P, Virolainen J, Nikkila H, et al. Associations between human aldosterone synthase (CYP11B2) gene polymorphisms and left ventricular size, mass, and function. Circulation. 1998 ; 97: 569-75 (Pubitemid 28090686)
43. Wang JG, Staessen JA. Genetic polymorphisms in the renin-angiotensin system: relevance for susceptibility to cardiovascular disease. Eur J Pharmacol. 2000 ; 410: 289-302 (Pubitemid 32008151)
44. Weber KT, Brilla CG, Campbell SE, Zhou G, Matsubaru L, Guarda E. Pathological hypertrophy with fibrosis: the structural basis for myocardial failure. Blood Press. 1992 ; 1: 75-85
45. Danser AHJ, Schalekamp ADH. Is there an internal cardiac renin-angiotensin system?. Heart. 1996 ; 76: 28-32
46. Schunkert H, Hengstenberg C, Holmer SR, Broeckel U, Luchner A, Muscholl MW, et al. Lack of association between a polymorphism of the aldosterone synthase gene and left ventricular structure. Circulation. 1999 ; 99: 2255-2260 (Pubitemid 29201131)
47. Mattei MG, Hubert C, Alhenc-Gelas F, Roeckel N, Corvol P, Soubrier F. Angiotensin I converting enzyme gene is on chromosome 17. Cytogenet Cell Genet. 1989 ; 51: 1041-1045
48. Jeunemaitre X. Genetics of the human renin angiotensin system. J Mol Med. 2008 ; 86: 637-641
49. Rigat B, Hubert C, Alhenc-Gelas F, Cambien F, Corvol P, Soubrier F. An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels. J Clin Invest. 1990 ; 86: 1343-1346 (Pubitemid 20370444)
50. Staessen JA, Wang JG, Ginocchio G, Petrov V, Saavedra AP, Soubrier F, et al. The deletion/insertion polymorphism of the converting-enzyme and cardiovascular-renal risk. J Hypertens. 1997a ; 15: 1579-1592 (Pubitemid 28029652)
51. Marian AJ, Yu QT, Workman R, Greve G, Roberts R. Angiotensin-converting enzyme polymorphism in hypertrophic cardiomyopathy and sudden cardiac death. Lancet. 1993 ; 342: 1085-1086 (Pubitemid 23338741)
52. Tesson F, Dufour C, Moolman JC, Carrier L, al-Mahdawi S, Chojnowska L, et al. The influence of the angiotensin I converting enzyme genotype in familial hypertrophic cardiomyopathy varies with the disease gene mutation. J Mol Cell Cardiol. 1997 ; 29: 831-838 (Pubitemid 27192888)
53. Dellgren G, Eriksson MJ, Blange I, Brodin LA, Rådegran K, Sylvén C. Angiotensin-converting enzyme gene polymorphism influences degree of left ventricular hypertrophy and its regression in patients undergoing operation for aortic stenosis. Am J Cardiol. 1999 ; 15 84: 909-913 (Pubitemid 29475075)
54. Gumprecht J, Zychma M, Grzeszczak W, ŁAcka B, Burak W, Mosur M, et al. Angiotensin I-converting enzyme and chymase gene polymorphisms-relationship to left ventricular mass in type 2 diabetes patients. Med Sci Monit. 2002 ; 8: 603-606
55. Schunkert H, Hense HW, Holmer SR, Stender M, Perz S, Keil U, et al. Association between a deletion polymorphism of the angiotensin-converting enzyme gene and left ventricular hypertrophy. N Engl J Med. 1994 ; 330: 1634-1638
56. Yamada Y, Ichihara S, Fujimura T, Yokota M. Lack of association of polymorphisms of the angiotensin converting enzyme and angiotensinogen genes with nonfamilial hypertrophic or dilated cardiomyopathy. Am J Hypertens. 1997 ; 10: 921-928 (Pubitemid 27380958)
57. Lindpaintner K, Lee M, Larson MG, Rao VS, Pfeffer MA, Ordovas JM, et al. Absence of association or genetic linkage between the angiotensin-converting- enzyme gene and left ventricular mass. N Engl J Med. 1996 ; 334: 1023-1028 (Pubitemid 26123778)
58. McLeod CJ, Bos JM, Theis JL, Edwards WD, Gersh BJ, Ommen SR, et al. Histologic characterization of hypertrophic cardiomyopathy with and without myofilament mutations. Am Heart J. 2009 ; 158: 799-805
59. Villard E, Tiret L, Visvikis S, Rakotovao R, Cambien F, Soubrier F. Identification of new polymorphisms of the angiotensin I-converting enzyme (ACE) gene, and study of their relationship to plasma ACE levels by two-QTL segregation-linkage analysis. Am J Hum Genet. 1996 ; 58: 1268-1278 (Pubitemid 26153839)
60. Jeunemaitre X, Inoue I, William C, Charru A, Tichet J, Powers M, et al. Haplotypes of angiotensinogen in essential hypertension. Am J Hum Genet. 1997 ; 60: 1448-1460 (Pubitemid 27258077)
61. Tang W, Devereux RB, Oberman A, Hopkins PN, Kitzman DW, Arnett DK. Associations between angiotensinogen gene variants and left ventricular mass and function in the HyperGEN study. Am Heart J. 2002 ; 143: 854-860 (Pubitemid 34595344)
62. Wong KK, Summers KM, Burstow DJ, West MJ. Angiotensin-converting enzyme and angiotensinogen genes in patterns of left ventricular hypertrophy and in diastolic dysfunction. Clin Exp Pharmacol Physiol. 1995 ; 22: 438-440
63. Staessen JA, Kuznetsova T, Wang JG, Emelianov D, Vlietinck R, Fagard R. M235T angiotensinogen gene polymorphism and cardiovascular renal risk. J Hypertens. 1999 ; 17: 9-17 (Pubitemid 29086182)
64. Sethi AA, Nordestgaard BG, Hansen AT. Angiotensinogen gene polymorphism, plasma angiotensinogen, and risk of hypertension and ischemic heart disease. A meta-analysis. Arterioscler Thromb Vasc Biol. 2003 ; 23: 1269-1275 (Pubitemid 36871283)
65. Wang AY, Chan JC, Wang M, Poon E, Lui SF, Li PK, et al. Cardiac hypertrophy and remodeling in relation to ACE and angiotensinogen genes genotypes in Chinese dialysis patients. Kidney Int. 2003 ; 63: 1899-1907 (Pubitemid 36513340)
66. Kim HS, Lee MM, Oh BH, Kim KI, Han KH, Park SK, et al. Synergistic effect of angiotensin-converting enzyme and angiotensinogen gene on cardiac hypertrophy. Int J Cardiol. 2000 ; 72: 151-161
67. Iwai N, Shimoike H, Ohmichi N, Kinoshita M. Angiotensinogen gene and blood pressure in the Japanese population. Hypertension. 1995 ; 25: 688-693
68. Ortlepp JR, Breithardt O, Ohme F, Hanrath P, Hoffmann R. Lack of association among five genetic polymorphisms of the renin-angiotensin system and cardiac hypertrophy in patients with aortic stenosis. Am Heart J. 2001 ; 141: 671-676 (Pubitemid 32260737)
69. Sanderson JE, Yu CM, Young RP, Shum IO, Wei S, Arumanayagam M, et al. Influence of gene polymorphisms of the renin-angiotensin system on clinical outcome in heart failure among the Chinese. Am Heart J. 1999 ; 137: 653-657 (Pubitemid 29173577)
70. Wagenaar LJ, Voors AA, Buikema H, van Gilst WH. Angiotensin receptors in the cardiovascular system. Can J Cardiol. 2002 ; 18: 1331-1339 (Pubitemid 36215784)
71. Bonnardeaux A, Davies E, Jeunemaitre X, Féry I, Charru A, Clauser E, et al. Angiotensin II type 1 receptor gene polymorphism in human essential hypertension. Hypertension. 1994 ; 24: 63-69 (Pubitemid 24195405)
72. Staessen JA, Ginocchio G, Wang JG, Saavedra AP, Soubrier F, Vlietinck R, et al. Genetic variability in the renin-angiotensin system: prevalence of alleles and genotypes. J Cardiovasc Risk. 1997b ; 4: 401-422 (Pubitemid 28078684)
73. Takami S, Imai Y, Katsuya T, Ohkubo T, Tsuji I, Nagai K, et al. Gene polymorphism of the renin-angiotensin system associates with risk for lacunar infarctions: the Ohasama Study. Am J Hypertens. 2000 ; 13: 121-127 (Pubitemid 30125633)
74. Tiret L, Bonnardeaux A, Poirier O, Ricard S, Marques-Vidal P, Evans A, et al. Synergistic effects of angiotensin-converting enzyme and angiotensin-II type 1 receptor gene polymorphisms on risk of myocardial infarction. Lancet. 1994 ; 344: 910-913 (Pubitemid 24295876)
75. Tomino Y, Makita Y, Shike T, Gohda T, Haneda M, Kikkawa R, et al. Relationship between polymorphism in the angiotensinogen, angiotensin-converting enzyme or angiotensin II receptor and renal progress in Japanese NIDDM patients. Nephron. 1999 ; 82: 139-144 (Pubitemid 29263973)
76. Sethupathy P, Borel C, Gagnebin M, Grant GR, Deutsch S, Elton TS, et al. Human microRNA-155 on chromosome 21 differentially interacts with its polymorphic target in the AGTR1 3′ untranslated region: a mechanism for functional single-nucleotide polymorphisms related to phenotypes. Am J Hum Genet. 2007 ; 81: 405-413 (Pubitemid 47236088)
77. Turu G, Szidonya L, Gaborik Z, Buday L, Spat A, Clark A, et al. Differential β-arrestin binding of AT1 and AT2 angiotensin receptors. FEBS Lett. 2006 ; 580: 41-45 (Pubitemid 43005309)
78. Mukawa H, Toki Y, Miyazaki Y, Matsui H, Okumura K, Ito T. Angiotensin II type 2 receptor blockade partially negates antihypertrophic effects of type 1 receptor blockade on pressure-overload rat cardiac hypertrophy. Hypertension Res. 2003 ; 26: 89-95 (Pubitemid 36193103)
79. Matsubara H. Pathophysiological role of angiotensin II type 2 receptor in cardiovascular and renal diseases. Circ Res. 1998 ; 83: 1182-1192
80. Wharton J, Morgan K, Rutherford RAD, Catravas JD, Chester A, Whitehead BF, et al. Differential distribution of AT2 receptors in the normal and failing human heart. J Pharmacol Exp Ther. 1998 ; 284: 323-336 (Pubitemid 28109563)
81. Tsutumi Y, Matsubara H, Ohkubo N, Mori Y, Nozawa Y, Murasawa S, et al. Angiotensin II type 2 receptor is upregulated in human heart with interstitial fibrosis, and cardiac fibroblasts are the major cell type for its expression. Circ Res. 1998 ; 83: 1035-1046 (Pubitemid 28520933)
82. Katsuya T, Horiuchi M, Minami S, Koike G, Santoro NF, Hsueh AJ, et al. Genomic organization and polymorphism of human angiotensin II type 2 receptor: no evidence for its gene mutation in two families of human premature ovarian failure syndrome. Mol Cell Endocrinol. 1997 ; 127: 221-228 (Pubitemid 27148381)
83. White PC. Disorders of aldosterone biosynthesis and action. N Engl J Med. 1994 ; 331: 250-258
84. Curnow KM, Tusie-Luna MT, Pascoe L, Natarajan R, Gu JL, Nadler JL, et al. The product of the CYP11B2 gene is required for aldosterone biosynthesis in the human adrenal cortex. Mol Endocrinol. 1991 ; 5: 1513-1522
85. Yoshida Y, Morimoto T, Takaya T, Kawamura T, Sunagawa Y, Wada H, et al. Aldosterone signaling associates with p300/GATA4 transcriptional pathway during the hypertrophic response of cardiomyocytes. Circ J. 2010 ; 74: 156-162
86. Tsybouleva N, Zhang L, Chen S, Patel R, Lutucuta S, Nemoto S, et al. Aldosterone, through novel signaling proteins, is a fundamental molecular bridge between the genetic defect and the cardiac phenotype of hypertrophic cardiomyopathy. Circulation. 2004 ; 109: 1284-1291 (Pubitemid 38372788)
87. White PC, Slutsker L. Haplotype analysis of CYP11B2. Endocr Res. 1995 ; 21: 437-442
88. Bureik M, Hübel K, Dragan CA, Scher J, Becker H, Lenz N, et al. Development of test systems for the discovery of selective human aldosterone synthase (CYP11B2) and 11beta-hydroxylase (CYP11B1) inhibitors. Discovery of a new lead compound for the therapy of congestive heart failure, myocardial fibrosis and hypertension. Mol Cell Endocrinol. 2004 ; 217: 249-254 (Pubitemid 38596650)
89. Bleumink GS, Schut AF, Sturkenboom MC, Deckers JW, van Duijn CM, Stricker BH. Genetic polymorphisms and heart failure. Genet Med. 2004 ; 6: 465-474 (Pubitemid 39576538)
90. Chai W, Hoedemaekers Y, van Schaik RH, van Fessem M, Garrelds IM, Saris JJ, et al. Cardiac aldosterone in subjects with hypertrophic cardiomyopathy. J Renin Angiotensin Aldosterone Syst. 2006 ; 7: 225-230 (Pubitemid 46380773)
91. Lala DS, Rice DA, Parker KL. Steroidogenic factor I, a key regulator of steroidogenic enzyme expression, is the mouse homolog of fushi tarazufactor I. Mol Endocrinol. 1992 ; 6: 1249-1258
92. Urata H, Kinoshita A, Perez DM, Misono KS, Bumpus FM, Graham BM, et al. Cloning of the gene and cDNA for human heart chymase. J Biol Chem. 1991 ; 266: 17173-17179 (Pubitemid 21907921)
93. Hamon M, Amant C, Bauters C, Richard F, Helbecque N, McFadden E, et al. Association of angiotensin converting enzyme and angiotensin II type 1 receptor genotypes with left ventricular function and mass in patients with angiographically normal coronary arteries. Heart. 1997 ; 77: 502-505 (Pubitemid 27294686)
94. Funada A, Konno T, Fujino N, Muramoto A, Hayashi K, Tsubokawa T, et al. Impact of renin-angiotensin system polymorphisms on development of systolic dysfunction in hypertrophic cardiomyopathy. Evidence from a study of genotyped patients. Circ J. 2010 ; 74: 2674-2680
95. Blauwet LA, Ackerman MJ, Edwards WD, Riehle DL, Ommen SR. Myocardial fibrosis in patients with symptomatic obstructive hypertrophic cardiomyopathy: correlation with echocardiographic measurements, sarcomeric genotypes, and pro-left ventricular hypertrophy polymorphisms involving the renin-angiotensin-aldosterone system. Cardiovasc Pathol. 2009 ; 18: 262-268
96. Colhoun HM, McKeigue PM, Davey Smith G. Problems of reporting genetic associations with complex outcomes. Lancet. 2003 ; 361: 865-872 (Pubitemid 36331853)
97. Ishanov A, Okamoto H, Watanabe M, Yoneya K, Nakagawa I, Kumamoto H, et al. Angiotensin II type 1 receptor gene polymorphisms in patients with cardiac hypertrophy. Jpn Heart J. 1998 ; 39: 87-96 (Pubitemid 28105434)
98. Tesson F, Charron P, Peuchmaurd M, Nicaud V, Cambien F, Tiret L, et al. Characterization of a unique genetic variant in the beta1-adrenoceptor gene and evaluation of its role in idiopathic dilated cardiomyopathy. J Mol Cell Cardiol. 1999 ; 31: 1025-1032 (Pubitemid 29241538)
99. McNamara DM, Holubkov R, Postava L, Janosko K, MacGowan GA, Mathier M, et al. Pharmacogenetic interactions between angiotensin-converting enzyme inhibitor therapy and the angiotensin converting enzyme deletion polymorphism in patients with congestive heart failure. J Am Coll Cardiol. 2004 ; 44: 2019-2026 (Pubitemid 39473288)
100. Lim DS, Lutucuta S, Bachireddy P, Youker K, Evans A, Entman M, et al. Angiotensin II blockade reverses myocardial fibrosis in a transgenic mouse model of human hypertrophic cardiomyopathy. Circulation. 2001 ; 103: 789-791 (Pubitemid 32163874)
101. Li L, Zhou N, Gong H, Wu J, Lin L, Komuro I, et al. Comparison of angiotensin II type 1-receptor blockers to regress pressure overload-induced cardiac hypertrophy in mice. Hypertens Res. 2010 ; 33: 1289-1297